MiniMed Group, Inc. (MMED) · Sep 1, 2026 · Earnings

MiniMed beats Q1 revenue expectations, but profit nearly disappears

Miss — Operating income $5M vs ~$36.6M consensus EBIT; GAAP EPS $0.00 vs ~$0.10-$0.12 adjusted consensus

MiniMed’s Q1 sales topped consensus, yet operating income and EPS lagged sharply as costs and dilution overwhelmed growth.

The market expected roughly $828M of revenue and about $0.10-$0.12 of adjusted EPS. The published consensus called for approximately $828.43M in revenue, adjusted EPS near $0.10-$0.12, and EBIT of roughly $36.6M.

MetricQ1 FY27Q1 FY26Market read
Net sales$843M (Financial Highlights)$723MAbove ~$828M consensus
Organic revenue growth15.8% (Organic Revenue table)—Above prior FY27 framework of approximately 10%
Operating income$5M (Income Statement)$(13)MWell below ~$36.6M consensus EBIT
Net income attributable to Company$0M (Income Statement)$(19)M—
Diluted EPS$0.00 (Income Statement)$(0.08)Below adjusted consensus of ~$0.10-$0.12
Weighted average shares281.0M (Income Statement)252.8MHigher dilution
CGM sales$431M (Segment results)$360MUp 19.9%

Revenue was the clear beat, but the quality of that beat was mixed. Worldwide sales reached $843M, up 16.6% reported and 15.8% organically, exceeding consensus by roughly $15M. The underlying growth still cleared the company’s roughly 10% FY27 organic-growth framework, but the quarter included a larger extra-week benefit than the annual outlook had assumed, reducing the upside’s persistence.

Profitability was the decisive miss. Operating income improved from a $13M loss to only $5M of profit, while the market had been looking for EBIT around $36.6M. The filing gives no adjusted-profit bridge explaining the gap, so the bottom-line comparison is not perfectly apples-to-apples; nevertheless, reported GAAP EPS was $0.00 and net income attributable to the company was effectively zero. Expenses also remained heavy: selling, general and administrative costs rose to $312M from $283M, and weighted-average shares increased to 281.0M from 252.8M.

The growth engine is working, but this quarter does not yet prove operating leverage. CGM revenue rose 19.9% to $431M, pumps grew 21.5% to $144M, and international sales increased 18.1% to $603M (Segment results). The company also said its pipeline advanced ahead of schedule, including FDA submission for MiniMed Fit and completion of Vivera pivotal-trial enrollment. 〔0〕 Those developments support the longer-term product story, but they do not offset the near-term earnings miss. Net read: a revenue beat overshadowed by unexpectedly weak profitability.

What to watch next

Management's September 1 earnings call

Original filing on SEC EDGAR

MiniMed beats Q1 revenue expectations, but profit nearly disappears | MMED Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.